Asio Capital LLC Cuts Position in IQVIA Holdings Inc. (NYSE:IQV)

Asio Capital LLC lowered its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 59.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,304 shares of the medical research company’s stock after selling 6,233 shares during the period. Asio Capital LLC’s holdings in IQVIA were worth $846,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. Capital Performance Advisors LLP purchased a new stake in IQVIA in the third quarter worth approximately $27,000. Park Place Capital Corp purchased a new stake in shares of IQVIA in the 3rd quarter valued at $28,000. Avior Wealth Management LLC grew its holdings in shares of IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 87 shares during the last quarter. Assetmark Inc. lifted its stake in IQVIA by 612.5% in the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after purchasing an additional 196 shares during the last quarter. Finally, UMB Bank n.a. boosted its position in IQVIA by 74.4% during the third quarter. UMB Bank n.a. now owns 232 shares of the medical research company’s stock valued at $55,000 after buying an additional 99 shares during the period. 89.62% of the stock is currently owned by institutional investors.

IQVIA Price Performance

Shares of NYSE IQV opened at $204.54 on Friday. The company has a 50 day simple moving average of $199.71 and a two-hundred day simple moving average of $221.06. IQVIA Holdings Inc. has a fifty-two week low of $187.62 and a fifty-two week high of $261.73. The company has a market capitalization of $37.12 billion, a price-to-earnings ratio of 26.84, a P/E/G ratio of 2.14 and a beta of 1.48. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on IQV. Leerink Partners reiterated an “outperform” rating and issued a $248.00 price objective (down previously from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. StockNews.com lowered shares of IQVIA from a “buy” rating to a “hold” rating in a report on Thursday, November 28th. Deutsche Bank Aktiengesellschaft lowered their price objective on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a research note on Friday, November 1st. The Goldman Sachs Group cut their target price on IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Finally, Barclays dropped their price objective on IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Four investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $255.71.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.